This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Cognitive dysfunction	Mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3)	Cell culture and mouse studies suggest the MLK3 inhibitor URMC-099 could be used to treat HIV-associated neurocognitive disorders (HAND). MLK3 has been associated with mediating neurotoxicity in mouse models for HIV-1 encephalitis. In cell-based and coculture models for HAND-associated neuroinflammation, URMC-099 decreased inflammatory cytokine levels and phagocytosis of axons compared with saline. In mouse models for HAND, URMC-099 decreased inflammatory cytokines and cortical dendritic spine elimination in the CNS compared with saline. Next steps include evaluating URMC-099 in a humanized mouse model for active HIV infection. *SciBX* 6(26); doi:10.1038/scibx.2013.663 Published online July 11, 2013	Patent application filed; available for licensing	Marker, D.F. *et al. J. Neurosci.*; published online June 12, 2013; doi:10.1523/JNEUROSCI.0598-13.2013 **Contact:** Daniel F. Marker, University of Rochester, Rochester, N.Y. e-mail: daniel_marker@urmc.rochester.edu